ClinicalTrials.Veeva

Menu
S

Syrentis Clinical Research | Santa Ana, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Relamorelin
Aducanumab
Ecopipam
Bococizumab
Seltorexant
Gantenerumab
Aticaprant
Simufilam
Dasotraline
Pimavanserin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 91 total trials

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). A...

Enrolling
Early Alzheimer's Disease
Biological: MK-2214
Drug: Placebo

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer...

Active, not recruiting
Alzheimer Disease 6
Cognitive Impairment
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling
Treatment Resistant Depression
Device: Vagus Nerve Stimulation (VNS)

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting
Depressive Disorder, Major
Drug: Aticaprant

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild c...

Enrolling
Alzheimers Disease
Drug: Trontinemab
Other: Placebo

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug
Locations recently updated

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on...

Enrolling
Depressive Disorder, Major
Drug: JNJ-89495120
Drug: Placebo

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:1. Is SN...

Enrolling
Moderate Alzheimer Disease
Biological: SNK01
Other: Placebo

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study.Participants who complete...

Invitation-only
Alzheimer Disease
AD
Device: Sensory Stimulation System (GS120) - Active
Locations recently updated

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Enrolling
Alzheimers Disease
Other: No Intervention

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Active, not recruiting
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Lilly logo
Allergan logo
Biogen logo
Otsuka logo
Roche logo
AbbVie logo
A
E
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems